Abiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prostate cancer, which is otherwise driven by intratumoral androgen synthesis 1,2 . Abiraterone is metabolized in patients to Δ 4 -abiraterone (D4A), which has even greater anti-tumour activity and is structurally similar to endogenous steroidal 5α-reductase substrates, such as testosterone 3 . Here, we show that D4A is converted to at least three 5α-reduced and three 5β-reduced metabolites in human serum. The initial 5α-reduced metabolite, 3-keto-5α-abiraterone, is present at higher concentrations than D4A in patients with prostate cancer taking abiraterone, and is an androgen receptor agonist, which promotes prostate cancer progression. In a clinical trial of abiraterone alone, followed by abiraterone plus dutasteride (a 5α-reductase inhibitor), 3-keto-5α-abiraterone and downstream metabolites were depleted by the addition of dutasteride, while D4A concentrations rose, showing that dutasteride effectively blocks production of a tumour-promoting metabolite and permits D4A accumulation. Furthermore, dutasteride did not deplete the three 5β-reduced metabolites, which were also clinically detectable, demonstrating the specific biochemical effects of pharmacological 5α-reductase inhibition on abiraterone metabolism. Our findings suggest a previously unappreciated and biochemically specific method of clinically fine-tuning abiraterone metabolism to optimize therapy.
metabolites downstream of D4A ( Fig. 1a and Extended Data Fig. 1 ). Mass spectrometry showed conversion from Abi and D4A to all three 5α-reduced metabolites, interconversion among the three 5α-reduced metabolites, and interconversion among the three 5β-reduced metabolites in the LAPC4, C4-2 and VCaP prostate cancer cell lines ( Fig. 1b and Extended Data Fig. 2 ). Direct incubation of LNCaP and LAPC4 human prostate cancer cells with D4A resulted in conversion to 5α-Abi and 3α-OH-5α-Abi, as detected using high-performance liquid chromatography (HPLC) with ultraviolet absorption (Extended Data Fig. 3a, d ), and treatment with 5α-Abi yielded conversion to 3α-OH-5α-Abi (Extended Data Fig. 3b ). The reversibility of this reaction is shown by detection of 5α-Abi after 3α-OH-5α-Abi treatment, particularly in LAPC4 cells (Extended Data Fig. 3c ); however, reduction to 3α-OH-5α-Abi appears to be the preferred reaction direction. Similarly, in mice, 5α-Abi was preferentially converted to 3α-OH-5α-Abi, although the reverse reaction was also detected (Fig. 1c ). 3β-OH-5α-Abi was also oxidized to 5α-Abi and converted to 3α-OH-5α-Abi. Reflecting the irreversible nature of steroid 5α-reduction, no Abi, D4A, or 5βreduced metabolites were detected in mice after treatment with any of the 5α-reduced Abi metabolites. Furthermore, all six metabolites were detected in the sera of 12 patients with CRPC undergoing treatment with Abi acetate (Fig. 1d , Extended Data Fig. 4 and Extended Data Table 1 ). Together, these data support a model in which once D4A is 5α-reduced to 5α-Abi, 3-keto reduction to 3-(α and β)-OH isomers and the reverse reactions occur, both in prostate cancer cells and in vivo.
Steroid 5α-reduction preserves the steroid planar structure and is essential for the regulation of biologically active androgens (that is, conversion of testosterone to DHT and Δ 4 -androstenedione to 5α-androstanedione (5α-dione)) 8, 9 . On the other hand, steroid 5β-reduction disrupts the planar conformation by introducing a 90° bend, which generally inactivates steroid hormones and facilitates their clearance. We therefore focused subsequent studies on the pathway and metabolites of D4A 5α-reduction. Synthesis of 5α-Abi and 3α-OH-5α-Abi is facilitated by upstream conversion of Abi to D4A by 3βHSD (Extended Data Fig. 5a ). In cells without endogenous steroid-5α-reductase (SRD5A) expression, conversion of D4A to 5α-Abi is enabled by expression of either SRD5A1 or SRD5A2 (Extended Data Fig. 5b ). In LAPC4 cells, which predominantly express SRD5A1 (ref. 8) , genetically silencing SRD5A1 (Extended Data Fig. 5c ), or pharmacological blockade using the SRD5A1 inhibitor LY191704 (ref. 10) or clinically achievable concentrations of the dual isoenzyme inhibitor dutasteride 11 , blocked conversion of D4A to 5α-Abi and 3α-OH-5α-Abi (Extended Data Fig. 5d ). The aldo-keto reductase isoenzyme AKR1C2 is thought to be the predominant 3-keto reductase that converts the 3-keto steroid DHT to 5α-androstane-3α,17β-diol 12 . We found that AKR1C2 expression also enabled the reduction of 5α-Abi to 3α-OH-5α-Abi (Extended Data Fig. 5e ).
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Next, we investigated the effects of 5α-reduced Abi metabolites on the androgen pathway. 5α-reduction of D4A to 5α-Abi and 3α-OH-5α-Abi is accompanied by attenuation or loss of inhibition of CYP17A1, 3βHSD and SRD5A ( Fig. 2a -c), as assessed by conversion of [ 3 H]pregnenolone to DHEA, [ 3 H]DHEA to Δ 4 -androstenedione, and [ 3 H]Δ 4 -androstenedione to 5α-dione, respectively. The effects, or lack thereof, of D4A and 5α-Abi metabolites on 3βHSD are consistent with previous observations that endogenous Δ 4 , 3-keto-steroids inhibit 3βHSD and that 5α-reduction of Δ 4 , 3-keto-steroids leads to loss of their inhibitory activity 13 .
D4A and 5α-Abi have similar affinities for the Thr877Ala mutant androgen receptor in LNCaP cells and the wild-type androgen receptor in LAPC4 cells, whereas 3α-OH-5α-Abi and Abi have lower affinities ( Fig. 2d ). To assess the consequences of 5α-Abi binding to the androgen receptor, we measured expression of androgen-responsive genes. Treatment with 5α-Abi resulted in expression of androgenresponsive genes in LAPC4 and LNCaP cells ( Fig. 2e-g) . These genes were expressed to a lower level after 3α-OH-5α-Abi treatment. The delayed and modest effect of 3α-OH-5α-Abi on induction of prostatespecific antigen (PSA) is consistent with its low binding affinity for the androgen receptor and the modest conversion of 3α-OH-5α-Abi to 5α-Abi, that appears to occur to a greater extent in LAPC4 than in LNCaP cells (Extended Data Fig. 3c ). Using a cDNA microarray and Gene Set Enrichment Analysis we found that 5α-Abi stimulates androgen receptor signature genes 14 (Extended Data Fig. 6a , b) and that 81% of genes regulated by 5α-Abi are also regulated by DHT (Extended Data Fig. 6c , d and Extended Data Table 2 ). To test the effect of androgen receptor stimulation by 5α-Abi on tumour growth, we treated mice bearing CRPC xenografts with 5α-Abi or 3α-OH-5α-Abi. 5α-Abi significantly shortened progression-free survival (P < 0.01), whereas 3α-OH-5α-Abi had no detectable effect when compared to untreated mice ( Fig. 2h ). We also tested all three 5β-reduced Abi metabolites for effects on androgen-responsive gene expression and confirmed that perturbation of the steroid planar structure is accompanied by the absence of metabolite activity ( Fig. 2i ).
We hypothesized that, when treated with Abi, prostate cancer cells might develop the capacity to augment the conversion of D4A to 5α-Abi by upregulating SRD5A. VCaP and LNCaP cells were cultured for 6 months with D4A or Abi, along with DHEA, to mimic the human adrenal androgen milieu ( Fig. 3a ). Cells propagated in longterm culture with D4A and Abi exhibited increased SRD5A enzyme activity, as assessed by conversion of [ 3 H]Δ 4 -androstenedione to 5α-reduced androgens, [ 3 H]testosterone to DHT, and D4A to 5αreduced Abi metabolites (Fig. 3b, c) . Increased SRD5A enzyme activity was accompanied by a predominant increase in SRD5A1 mRNA (Extended Data Fig. 7a ) and protein expression ( Fig. 3d, e ). Unlike Abi or D4A treatment, enzalutamide treatment did not induce an increase in SRD5A (Extended Data Fig. 7b , c). No change in AR-V7 (the androgen receptor splice variant) resulted from Abi or D4A treatment (Extended Data Fig. 7d ). Together, these results suggest that a selective growth advantage results from depleting the anti-tumour Abi
LETTER RESEARCH activity associated with D4A and/or increasing the androgen receptor agonist activity of 5α-Abi.
Next, we hypothesized that the increased 5α-Abi:D4A ratio (approximately 2.5:1) would be specifically and clinically reversible by dual SRD5A isoenzyme inhibition with dutasteride in patients being treated with Abi acetate. A phase II clinical trial (NCT01393730) involving treatment with Abi acetate (1,000 mg daily) plus prednisone (5 mg daily) for 2 months (2 cycles), followed by the addition of dutasteride at the start of cycle 3 (3.5 mg once daily; Fig. 4a ), is ongoing in men with metastatic CRPC. The results from sixteen patients who had blood collected on Abi acetate alone (start of cycle 3) and after the addition of dutasteride (start of cycles 4 and 7) have been analysed. Notably, there was an 89% decline in the mean concentration of 5α-Abi after the addition of dutasteride (cycle 3: 25.8 nM versus cycle 4: 2.9 nM; P < 0.001; Fig. 4d ). The other two 5α-reduced metabolites downstream of SRD5A exhibited similar declines (92% decline in 3α-OH-5α-Abi and 73% decline in 3β-OH-5α-Abi), further corroborating the ability of dutasteride to block 5α-reduction of D4A in patients. Pharmacological inhibition of SRD5A nearly doubled the mean serum concentration of D4A (cycle 3: 9.9 nM versus cycle 4: 18.2 nM; P = 0.002; Fig. 4c ). Unexpectedly, the addition of dutasteride also nearly doubled the mean concentration of Abi (cycle 3: 191.2 nM versus cycle 4: 372.4 nM; P = 0.051; Fig. 4b ), although this difference did not reach statistical significance. Concentrations of Abi, D4A and 5α-Abi metabolites at cycle 7, the second time point after addition of dutasteride, were similar to those at cycle 4, although the differences from Abi alone at baseline were slightly lessened ( Fig. 4 and Extended Data Table 3 ). Finally, and in sharp contrast to the substantial decline in 5α-Abi metabolites after the addition of dutasteride, there was no decrease in any of the three 5β-reduced Abi metabolites, supporting the idea that SRD5A inhibition has a very specific biochemical effect on 5α-Abi metabolism ( Fig. 4e ). Together, these findings demonstrate that the elevated 5α-Abi:D4A ratio can be pharmacologically, specifically and clinically reversed by dutasteride.
CYP17A1 inhibition by Abi is clinically incomplete, as has been demonstrated by the persistence of residual urinary androgen metabolites 15 and high residual serum concentrations of DHEA-sulfate, the major androgen produced from the human adrenal gland 16 , in patients being treated with Abi. Molecular aberrations that sustain androgen receptor signalling contribute to the development of CRPC 17 and also drive Abi resistance 18, 19 . Together, these studies suggest that reversal of sustained androgen receptor signalling should have a therapeutic benefit in at least a subset of patients with Abi resistant disease.
Some sustained androgen receptor signalling is due to the continuous supply of endogenous androgens (testosterone and/or DHT) provided by maintained steroidogenesis. Preclinical models suggest that Abi resistance can be driven by upregulation of steroidogenic enzymes 20 . Our findings demonstrate that, as well as providing potent endogenous androgens, steroidogenic enzymes may also regulate Abi metabolism, for example by increasing SRD5A activity and thereby hastening the elimination of the anti-tumour activity associated with D4A (ref.
3) by converting it to 5α-Abi, which instead has tumourpromoting androgen receptor agonist activity. Consistent with our findings, SRD5A is one of the most upregulated steroidogenic-enzyme transcripts in another model of Abi resistance 20 .
The coordinate effects of steroidogenic enzymes on endogenous steroids, compared to the effects on Abi, should be considered in view LAPC4 cells were treated with [ 3 H]AD and the indicated drugs, and flux to 5α-dione was assessed after 24 h of incubation. **P < 0.01; t-test. d, 5α-Abi and D4A bind comparably to the androgen receptor. LNCaP and LAPC4 express the mutated and wild-type androgen receptor, respectively, and were incubated with [ 3 H]R1881 and the indicated compounds for 30 min. Intracellular radioactivity was normalized to protein concentration. e, f, 5α-Abi stimulates androgen-responsive gene expression in LAPC4 and LNCaP cells. Delayed and more modest PSA (also known as KLK3) expression is stimulated by 3α-OH-5α-Abi. g, Dose-dependent stimulation of PSA expression by 5α-Abi in LAPC4 cells. h, Treatment with 5α-Abi (n = 10 mice) but not 3α-OH-5α-Abi (n = 9 mice) hastens VCaP CRPC xenograft growth compared with control treatment (n = 9 mice) in orchiectomized mice. Treatment with the indicated compounds began when CRPC tumours reached 100 mm 3 and progression-free survival was assessed as the time until there was >30% growth for two sequential measurements. **P < 0.01 for the difference between 5α-Abi and ctrl; log-rank test. i, 5β-reduced Abi metabolites do not stimulate PSA expression. Expression is normalized to RPLP0 and vehicle expression in e-g and i. All error bars represent s.d. All experiments in a-g and i were performed at least three times.
of our findings on extensive steroidogenic metabolism of Abi. For example, increased SRD5A enzyme activity should have concordant favourable effects on tumour growth by increasing DHT synthesis and converting D4A to 5α-Abi. On the other hand, increasing 3βHSD activity would be expected to have discordant effects, as it is required for synthesis of testosterone and DHT (which promote tumour growth) but increases the conversion of Abi to D4A (which is detrimental to tumour growth). In this context, it is likely that the net effect of increased intratumoral 3βHSD activity will be beneficial, because the endogenous substrates (DHEA, Δ 5 -androstenediol and pregnenolone) are probably preferred over D4A. A third enzymatic reaction that is relevant both to endogenous 5α-reduced androgens and 5α-Abi is 3α-OH-oxidation to 3-keto-steroids. Oxidation or 'back-conversion' of 3α-OH-5α-androstanediol, which does not stimulate the androgen receptor, to 3-keto-DHT can stimulate androgen receptor signalling 21, 22 . The net effect of this reaction on androgens and Abi metabolism is therefore expected to be concordant and stimulatory because, in addition to increasing DHT synthesis, conversion of 3α-OH-5α-Abi to 5α-Abi also increases affinity for the androgen receptor (Fig. 2d) , and stimulates androgen-responsive gene expression ( Fig. 2e -g) and tumour growth (Fig. 2h ).
Notwithstanding these considerations, the majority of Abi metabolites found in serum probably form independently of tumour metabolism and result from the activity of hepatic enzymes. Although we found that prostate cancer cell lines readily 5α-reduce D4A, no prostate cancer-dependent 5β-reduction was observed. Both steroid 5αand 5β-reductase reactions are abundant in the liver. The contributions to treatment response of D4A depletion by intrinsic tumour SRD5A versus extrinsic metabolism remain to be determined. Nonetheless, in our clinical study, adding dutasteride to treatment with Abi acetate resulted in an approximately 90% decline in circulating concentrations of 5α-Abi, the immediate product of D4A 5α-reduction, with similar declines in the other 5α-Abi metabolites. D4A concentrations concomitantly rose after the addition of dutasteride, supporting the specific pharmacological effect of dutasteride on D4A metabolism. Numerically, there was also a rise in Abi concentration, and although this increase did not reach the generally accepted level of statistical significance (P = 0.051), it does raise the possibility that SRD5A provides an important mechanism of Abi clearance, at least in a subset of patients.
The absence of any effect on 5β-reduced Abi metabolites demonstrates the remarkable specificity of dutasteride on 5α-reduction of D4A. The presence and maintenance of 5β-reduced metabolites further suggests an 'escape' mechanism of D4A metabolism that occurs with pharmacological 5α-reductase inhibition, raising the possibility that concentrations of D4A and perhaps Abi might be further elevated by 5β-reductase inhibition, resulting in further therapeutic effects.
Our studies demonstrate that SRD5A inhibition has a clear and specific biochemical effect on D4A metabolism in patients treated with Abi. This effect would be expected to intensify the benefit of Abi therapy. The clinical benefit of fine-tuning Abi metabolism with SRD5A inhibition requires further investigation in randomized trials.
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METHODS
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Cell lines, drugs and constructs. LNCaP, 293T and VCaP cells were purchased from the American Type Culture Collection and maintained in RPMI-1640 (LNCaP) or DMEM (293T and VCaP) with 10% FBS (Gemini bio-products). The LAPC4 cell line was provided by C. Sawyers and grown in Iscove's modified Dulbecco's medium with 10% FBS. Stable LAPC4 cell lines with SRD5A1 knockdown were established as previously described 8 . Plasmid pcDNA3-c17 (a gift from W. Miller) was used to establish the 293T stable cell line expressing human CYP17A1 as described 23 . Cell lines were authenticated by DDC Medical and determined to be mycoplasma free with primers 5′-ACACCATGGGAGCTGGTAAT-3′ and 5′-GTTCATCGACTTTCAGACCCAAGGCAT-3′. Dutasteride was purchased from Medkoo Biosciences. Enzalutamide was obtained from Medivation. The AKR1C2 expression plasmid was a gift from T. Penning. Enzalutamide-resistant cells were cultured with DMSO or 1 μM or 10 μM enzalutamide for more than 6 months (LAPC4) or 10 weeks (VCaP) in the presence of 10 nM DHEA. Abi or D4A resistant cells were cultured as indicated in Fig. 3a . High-performance liquid chromatography. To measure cell line metabolism, 0.2 million cells per ml were seeded and incubated in 12-well plates for ~24 h before incubation with the indicated drugs or a mixture of 3 H-labelled (~1,000,000 c.p.m. per well; PerkinElmer) and non-radioactive androgens (final concentration, 100 nM) at 37 °C. Collected medium was treated with β-glucuronidase (Helix pomatia; Sigma-Aldrich), extracted with ethyl acetate: isooctane (1:1), and concentrated under nitrogen gas as described previously 24 .
To measure xenograft metabolism, 10 7 VCaP cells with Matrigel were injected subcutaneously into orchiectomized non-obese diabetic (NOD)-severe combined immunodeficient (SCID)-Il2rg −/− (NSG) mice with 5 mg, 90-day sustained-release DHEA pellets (Innovative Research of American). Xenografts (~1,000 mm 3 ) were removed, minced, and cultured in DMEM with 10% FBS at 37 °C with the indicated drugs. Aliquots of medium were collected at the indicated times. Collected medium was processed for HPLC with the same protocol as medium from cell lines.
HPLC analysis was performed on a Waters 717 Plus HPLC or an Agilent 1260 HPLC. Dried samples were reconstituted in 50% methanol and separated on a Kinetex 100 × 2.1 mm, 2.6 μm particle size C 18 reverse-phase column (Phenomenex) using a methanol/water gradient at 30 °C. The column effluent was analysed using a 254-nm UV-visible detector or β-RAM model 3 in-line radioactivity detector (IN/US Systems, Inc.) using Liquiscint scintillation cocktail (National Diagnostics). All HPLC studies were conducted in triplicate and repeated at least three times in independent experiments. Results are shown as mean ± s.d. Gene expression and immunoblotting. Cells were starved with phenol red-free and serum-free medium for at least 48 h before treatment with the indicated drugs and/or androgens. RNA extraction and cDNA synthesis were performed with the GenElute Mammalian Total RNA miniprep kit (Sigma-Aldrich) and iScript cDNA Synthesis Kit (Bio-Rad), respectively. Quantitative PCR (qPCR) analysis was conducted in triplicate in an ABI 7500 Real-Time PCR machine (Applied Biosystems) using iTaq Fast SYBR Green Supermix with ROX (Bio-Rad) and primers for TMPRSS2, PSA and RPLP0, as described previously 4 . SYBR Premix Ex TaqII (Takara) was used for SRD5A1, SRD5A2 and ARV7 detection. Primers used for androgen receptor detection were 5′-TCTTGTCGTCTTCGGAAATGT-3′ and 5′-AAGCCTCTCCTTCCTCCTGTA-3′ (ref. 25) . Primers used for ARV7 detection were 5′-CCATCTTGTCGTCTTCGGAAATGTTATGAAGC-3′ and 5′-TTTGAATGAGGCAAGTCAGCCTTTCT-3′ (ref. 26) . Accurate quantification of each mRNA was achieved by normalizing the sample values to RPLP0 and to vehicle-treated cells. Cell lysate (50 μg) was used for immunoblotting with rabbit anti-SRD5A1 (Abnova) and mouse anti-β-actin (Sigma-Aldrich) antibodies. Microarray study and analysis. LAPC4 cells were starved with phenol red-free and serum-free medium for at least 48 h before treatment with the indicated drugs and/or androgens, in biological triplicate. RNA was extracted with mirVana miRNA isolation kit (Life Technologies). The genomics core of Cleveland Clinic generated cDNA and performed the microarray with HumanHT-12 v4 Expression BeadChip and iScan (Illumina). Hybrid signals were analysed with Illumina GenomeStudio Software 2011.1 and normalized to the vehicle control group. Regulated genes are defined as detection P < 0.01, fold change (compared to control group) >1.55 or <0.5. Heatmap was generated with HemI software 27 . The complete results have been deposited in the NCBI Gene Expression Omnibus database under accession GSE75387.
Normalized, log 2 -transformed data were used for subsequent gene set enrichment carried out using R (http://www.R-project.org) and Bioconductor software 28 .
The 2,500 genes with the highest median absolute deviation were selected for analysis. Enrichment scores were calculated for the gene set C2 Collection (curated pathways) from the Molecular Signatures Database version 5.1 (MSigDB v5.1) using the Bioconductor package 'GSVA' 29 . Gene sets with a minimum of 10 genes and a maximum of 1,000 genes were included. Significance testing of enrichment scores was performed with a moderated t-statistic (false discovery rate (FDR) <0.01) using the Bioconductor package 'limma' . Separately, GSEA was used to correlate the 5α-Abi expression data with an androgen receptor-selective gene set described elsewhere 14 . The GSEA enrichment plot was generated as described elsewhere 30, 31 . Mouse xenograft studies. Male NSG mice, 6 to 8 weeks of age were obtained from the Cleveland Clinic Biological Resources Unit facility. All mouse studies were conducted under a protocol approved by the Cleveland Clinic Institutional Animal Care and Use Committee. 10 7 VCaP cells were injected subcutaneously with Matrigel. Once tumours reached 100 mm 3 (length × width × height × 0.52), mice were surgically orchiectomized and arbitrarily assigned to vehicle (n = 9), 5α-Abi (n = 10), or 3α-OH-5α-Abi (n = 9) treatment groups. Mice were injected intraperitoneally with 0.15 mL 5α-Abi and 3α-OH-5α-Abi (0.15 mmol kg −1 per day and 0.075 mmol kg −1 per day, respectively, in 5% benzyl alcohol and 95% safflower oil solution) every day for up to 20 days. Control groups were administered 0.15 ml 5% benzyl alcohol and 95% safflower oil solution via intraperitoneal injection every day. Tumour volume was measured every other day, and time to increase in tumour volume by 30% was determined (2 sequential increases). Mice were killed at treatment day 20. The significance of the difference between treatment groups was assessed by Kaplan-Meier survival analysis using a log-rank test in SigmaStat 3.5. AR competition assay. Cells were starved with phenol red-free and serum free-medium for at least 48 h and then treated with [ 3 H]R1881 and the indicated concentrations of drugs for 30 min. Cells were washed thoroughly with PBS and then lysed with RIPA buffer. Intracellular radioactivity was measured with a Beckman Coulter LS60001C liquid scintillation counter and normalized to the protein concentration as detected with a Wallac Victor2 1420 Multilabel counter (Perkin Elmer). Patient serum collection and drug extraction. Twelve patients with CRPC undergoing standard treatment with Abi acetate at Cleveland Clinic were consented under an Institutional Review Board-approved protocol (Case 7813). Blood was collected using Vacutainer Plus serum blood collection tubes (#BD367814, Becton Dickenson, Franklin Lakes, NJ), between 1 and 16 h after the 1000 mg daily dose of Abi acetate was administered, and allowed to clot. Tubes were centrifuged at 2500 r.p.m. or 1430g for 10 min. Serum aliquots were frozen at −80 °C until processing. To study the effect of dutasteride on Abi metabolism, serum samples were collected from patients treated on a phase II clinical trial at Dana-Farber Cancer Institute (NCT01393730). Each patient received Abi acetate (1,000 mg daily) plus prednisone (5 mg daily) for 2 cycles (8 weeks) and then additional treatment with dutasteride (3.5 mg daily) was initiated. Samples were collected on treatment with Abi alone and after addition of dutasteride (start of cycles 3, 4 and 7). Seventeen patients treated at this institution on this clinical trial had blood available from all 3 time points. One patient had Abi concentrations that were under the limit of detection and was later determine to have stopped treatment because of adverse effects and was therefore not included in the analysis. Drug metabolites and internal standard (d 4 -abiraterone, Toronto Research Chemicals Inc) were extracted from 100 μl of patient serum with methyl tert-butyl ether (Sigma Aldrich), evaporated under a stream of nitrogen gas and reconstituted in methanol:water (50:50) before mass spectrometry analysis. Standard curves were generated using human serum spiked with known concentrations of each metabolite to enable determination of unknown concentrations in patient samples. Mouse serum extraction. Mouse serum (20 μl) was precipitated with 500 μl methanol containing the internal standard (d 4 -abiraterone) the supernatant was then injected into the mass analyser. Standard curves were prepared with mice serum spiked with known metabolites concentrations for accurate determination of unknown metabolites concentrations. Cell line media extraction. Samples of medium (200 μl each) collected at different time points were extracted with methyl tert-butyl ether (Sigma Aldrich), evaporated under a stream of nitrogen gas and reconstituted in methanol:water (50:50) before mass spectrometry analysis. Mass spectrometry. Samples were analysed on a ultra high-performance liquid chromatography station (Shimadzu) with a DGU-20A3R degasser, 2 LC-30AD pumps, a SIL-30AC autosampler, a CTO-10A column oven and a CBM-20A system controller in tandem with a QTRAP 5500 mass spectrometer (AB Sciex). Drug metabolites were ionized using electrospray ionization in positive ion mode. Multiple reaction monitoring was used to follow mass transitions for Abi, IS, and the metabolites ( Supplementary Table 1 ). Owing to the similarity in structure and mass transitions for the metabolites it was necessary to separate them with LETTER RESEARCH 
